Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …

Early cancer detection has significant clinical value, but there remains no single method that
can comprehensively identify multiple types of early-stage cancer. Here, we report the …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

The mutational and phenotypic landscape of tumors is dynamic, requiring constant
monitoring of cancer patients to provide the most up-to-date and effective care. Circulating …

Only a minority of rheumatoid arthritis (RA) patients achieve disease remission, so the
exploration of additional pathogenic factors and the development of new therapeutics are …

This article reviews recent developments in the application of cell-free DNA-based liquid
biopsies to neurological diseases. Over the past few decades, an explosion of interest in the …

Background Liquid biopsy has been widely researched for early diagnosis, prognostication
and disease monitoring in lung cancer, but there is a need to investigate its clinical utility for …

Although cell-free DNA (cfDNA) is an emerging sepsis biomarker, the use of cfDNA,
especially as diagnostic and prognostic indicators, has surprisingly not been systemically …

DNA methylation profiles are in dynamic equilibrium via the initiation of methylation,
maintenance of methylation and demethylation, which control gene expression and …